Necroptosis-induced inflammation in lung cancer

Immunotherapy, a treatment method that activates the body`s immune system to fight cancer cells, is a key approach in treating lung cancer. However, despite its success, many patients unfortunately experience a relapse after some time. A significant challenge for doctors is the absence of reliable markers to predict who will respond well to immunotherapy and who will not. This is because of our incomplete understanding of the interactions among the immune system, cancer cells, and their surrounding environment. A key process involved in this is called necroptosis. This process functions as a `self-destruct mechanism` in cells, which, under certain conditions, can result in the death of cancer cells. Additionally, necroptosis plays a role in enhancing the immune system`s ability to fight against cancer cells. Therefore, it is vital to study how inflammation in cancer cells influences the immune system, as this can lead to advancements in lung cancer treatment. In studying how cancer cells stop the process of necroptosis, what happens when this process fails, and how necroptosis affects the relationship between the tumor and the immune system, we can gain essential new insights. These discoveries can help us find better ways to predict and understand the progression of lung cancer and other types of cancer. We anticipate that lung cancer blocks the process of necroptosis, thereby preventing inflammation and stopping the infiltration of immune cells. As a result, the tumor continues to grow as the immune system does not target it. To test our ideas, we use state-of-the-art technologies. We analyze human tissue samples and work with uniquely created mouse models. These models are established using advanced CRISPR-Cas9 technology, allowing us to investigate lung cancer through precise genetic modifications. Our research approach opens new perspectives on how lung cancer evades the immune system. Furthermore, our work is dedicated to achieving an in-depth understanding of the role that the necroptosis process plays in lung cancer. We aim to find new markers that reliably predict how well patients respond to immunotherapy. In the long term, our research findings could lead to specially tailored and more effective treatment methods, significantly improving the survival chances of lung cancer patients.